These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7369892)

  • 1. Effects of ticlopidine on thrombotic obstruction of A-V shunts and on dialysance of artificial kidneys.
    Maeda K; Usuda M; Kawaguchi S; Shinzato T; Saito A; Ohta K; Kobayashi K; Ohbayashi S; Narita M
    Artif Organs; 1980 Feb; 4(1):30-3. PubMed ID: 7369892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic effects of ticlopidine, acetylsalicyclic acid and dipyridamole in vascular shunt model in rats.
    Ashida S; Sakuma K; Abiko Y
    Thromb Res; 1980 Mar; 17(5):663-71. PubMed ID: 7385100
    [No Abstract]   [Full Text] [Related]  

  • 3. Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis--a multicenter collaborative double blind study.
    Kobayashi K; Maeda K; Koshikawa S; Kawaguchi Y; Shimizu N; Naito C
    Thromb Res; 1980 Oct; 20(2):255-61. PubMed ID: 7209880
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of a new platelet aggregation inhibitor, ticlopidine, in hemodialysis].
    Griffanti-Bartoli F; Altomonte F; Pitton L; Armani U; Piana A
    Arch Maragliano Patol Clin; 1979; 35(2):73-80. PubMed ID: 263724
    [No Abstract]   [Full Text] [Related]  

  • 5. Ticlopidine as an experimental antithrombotic agent.
    Vallée E; Maffrand JP; Bernat A; Delebassée D; Tissinier A
    Agents Actions Suppl; 1984; 15():50-9. PubMed ID: 6592945
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of ticlopidine on platelet function in normal volunteers and in patients with platelet hyperaggregability in vitro.
    Knudsen JB; Gormsen J
    Thromb Res; 1979; 16(5-6):663-71. PubMed ID: 524316
    [No Abstract]   [Full Text] [Related]  

  • 7. [Ticlopidine in heart surgery with cardiopulmonary by-pass (author's transl)].
    Renner C; Guilmet D; Curtet JM
    Nouv Presse Med; 1980 Nov; 9(43):3249-51. PubMed ID: 7454568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-thrombotic action of ticlopidine, a new platelet aggregation inhibitor.
    Tomikawa M; Ashida S; Kakihata K; Abiko Y
    Thromb Res; 1978 Jun; 12(6):1157-64. PubMed ID: 694822
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.
    Kohga S; Kinjo M; Tanaka K; Ogawa H; Ishihara M; Tanaka N
    Cancer Res; 1981 Nov; 41(11 Pt 1):4710-4. PubMed ID: 7306988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function.
    Picard-Fraire C
    Thromb Res Suppl; 1983; 4():119-28. PubMed ID: 6356462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis.
    Gröntoft KC; Mulec H; Gutierrez A; Olander R
    Scand J Urol Nephrol; 1985; 19(1):55-7. PubMed ID: 3895411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interactions of ticlopidine and aspirin in normal subjects.
    Thebault JJ; Blatrix CE; Blanchard JF; Panak EA
    J Int Med Res; 1977; 5(6):405-11. PubMed ID: 590598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiaggregatory, physiological and clinical effects of ticlopidine in subjects with peripheral atherosclerosis.
    Kirstein P; Jogestrand T; Johnsson H; Olsson AG
    Atherosclerosis; 1980 Aug; 36(4):471-80. PubMed ID: 7417366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of platelet aggregation by a new agent, Ticlopidine.
    Ashida SI; Abiko Y
    Thromb Haemost; 1979 Feb; 40(3):542-50. PubMed ID: 425067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
    Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-platelet drugs during chronic hemodialysis: an experience with ticlopidine, the 5-(o-chlorobenzyl)-4,5,6,7-tetrahydrothieno-[3,2-c] pyridine.
    Bono F; De Gasperi T; Zanelli P; Menta R; Castiglioni A; Savazzi GM; Cambi V
    Farmaco Prat; 1983 Dec; 38(12):451-5. PubMed ID: 6662220
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of long term administration of ticlopidine on platelet function and hemostatic variables.
    Conard J; Lecrubier C; Scarabin PY; Horellou MH; Samama M; Bousser MG
    Thromb Res; 1980 Oct; 20(1):143-8. PubMed ID: 7209871
    [No Abstract]   [Full Text] [Related]  

  • 18. The mechanisms of action of ticlopidine.
    Bruno JJ
    Thromb Res Suppl; 1983; 4():59-67. PubMed ID: 6356466
    [No Abstract]   [Full Text] [Related]  

  • 19. Preventive effects of Ticlopidine on the incidence of late A-V fistula thrombosis complications in haemodialyses patients.
    Janicki K; Bojarska-Szmygin A; Pietura R; Janicka L
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):215-8. PubMed ID: 15314987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticlopidine improves dialysis clearance of solutes in uremic patients by reducing blood clotting in dialyser fibers.
    Milutinović S; Gasparović V; Milutinović E; Buturović-Ponikvar J
    Int J Artif Organs; 1993 May; 16(5):249-52. PubMed ID: 8354583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.